Drugmaker Eli Lilly says its COVID-19 antibody drug helped prevent illness among residents and staff of nursing homes and other long-term care locations.
It’s the first major study to show an antibody medication may prevent disease. The drugmaker says residents and staff who got the drug had up to a 57% lower risk of getting COVID-19. Among nursing home residents only, there was up to an 80% reduction in risk.
US regulators last year allowed emergency use of the antibody treatment for mild or moderate COVID-19 cases that don’t require hospitalization. It’s a one-time dose given through an IV.
The study, conducted by the National Institutes of Health, involved more than 1,000 residents and staff at nursing homes and other long-term care locations.
In the US, those residents account for less than 1% of the population, but nearly 40% of deaths from COVID-19. The U.S. leads the world with more than 406,000 deaths.
Help us report truthfully on social media
As a multimedia journalist, my job is to take the quality, fact-based journalism produced by The Times of Israel newsroom and make it accessible across every platform — from Instagram posts to podcasts to short-form videos.
This is how many, especially young people, consume news these days. But misinformation is rampant on social media. Our team at ToI produces accurate, responsible short-form reporting on Israel and the Jewish world.
If you believe in the importance of factual social media journalism, please consider joining our reader support group, The Times of Israel Community. Your financial support is essential to sustain responsible multimedia reporting.
— Gabriella Jacobs, multimedia journalist
Support our work
Support our work
Already a member? Sign in to stop seeing this
You're a dedicated reader
We’re really pleased that you’ve read X Times of Israel articles in the past month.
That’s why we started the Times of Israel - to provide discerning readers like you with must-read coverage of Israel and the Jewish world.
So now we have a request. Unlike other news outlets, we haven’t put up a paywall. But as the journalism we do is costly, we invite readers for whom The Times of Israel has become important to help support our work by joining The Times of Israel Community.
For as little as $6 a month you can help support our quality journalism while enjoying The Times of Israel AD-FREE, as well as accessing exclusive content available only to Times of Israel Community members.
Thank you,
David Horovitz, Founding Editor of The Times of Israel
Join Our Community
Join Our Community
Already a member? Sign in to stop seeing this
From the Liveblog of
Thursday, January 21, 2021
Add ToI as a Preferred Source on Google
